INMUNE BIO INC. Cash and Cash Equivalents, Period Increase (Decrease)
INMUNE BIO INC. (INMB) reported Cash and Cash Equivalents, Period Increase (Decrease) of $52.84 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-03-03
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-12-31 was -$9.66M.
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-09-30 was $44.95M, a 130.58% increase year-over-year.
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-06-30 was -$5.82M.
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-03-31 was $23.37M.
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for fiscal 2021 was $52.84M, a 252.97% increase from fiscal 2020.
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for fiscal 2020 was $14.97M, a 119.86% increase from fiscal 2019.
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $6.81M.
- INMUNE BIO INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$1.18M, a 196.38% decline from fiscal 2017.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | -$9.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $35.29M derived: sum of 2 quarters · filed 2022-03-03 | $29.47M derived: sum of 3 quarters · filed 2022-03-03 | $52.84M 10-K · filed 2022-03-03 | ||||
| 2021-09-30 | $44.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $39.13M derived: sum of 2 quarters · filed 2021-11-03 | $62.50M 10-Q · filed 2021-11-03 | $60.16M derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2021-06-30 | -$5.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $17.55M 10-Q · filed 2021-08-04 | $15.21M derived: sum of 3 quarters · filed 2022-03-03 | $34.70M derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2021-03-31 | $23.37M 10-Q · filed 2021-05-05 | $21.03M derived: sum of 2 quarters · filed 2022-03-03 | $40.52M derived: sum of 3 quarters · filed 2022-03-03 | $39.41M derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2020-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $17.15M derived: sum of 2 quarters · filed 2022-03-03 | $16.04M derived: sum of 3 quarters · filed 2022-03-03 | $14.97M 10-K · filed 2022-03-03 | $14.97M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $19.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $18.38M derived: sum of 2 quarters · filed 2021-11-03 | $17.32M 10-Q · filed 2021-11-03 | $17.32M 10-Q · filed 2020-11-05 | $16.93M derived: sum of 4 quarters · filed 2021-11-03 | |||
| 2020-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$2.18M 10-Q · filed 2021-08-04 | -$2.18M 10-Q · filed 2020-08-05 | -$2.57M derived: sum of 3 quarters · filed 2021-08-04 | -$4.55M derived: sum of 4 quarters · filed 2021-08-04 | |||
| 2020-03-31 | -$1.06M 10-Q · filed 2021-05-05 | -$1.06M 10-Q · filed 2020-05-14 | -$1.45M derived: sum of 2 quarters · filed 2021-05-05 | -$3.43M derived: sum of 3 quarters · filed 2021-05-05 | -$118.40K derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | -$387.14K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$2.37M derived: sum of 2 quarters · filed 2021-03-04 | $946.60K derived: sum of 3 quarters · filed 2021-03-04 | $6.81M 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.33M derived: sum of 2 quarters · filed 2020-11-05 | $7.20M 10-Q · filed 2020-11-05 | $6.73M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $3.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $9.18M 10-Q · filed 2020-08-05 | $8.71M derived: sum of 3 quarters · filed 2020-08-05 | $8.26M derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $5.86M 10-Q · filed 2020-05-14 | $5.40M derived: sum of 2 quarters · filed 2020-05-14 | $4.94M derived: sum of 3 quarters · filed 2020-05-14 | $4.09M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | -$464.66K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$922.21K derived: sum of 2 quarters · filed 2020-03-11 | -$1.77M derived: sum of 3 quarters · filed 2020-03-11 | -$1.18M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | -$457.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$1.31M derived: sum of 2 quarters · filed 2019-11-08 | -$719.85K 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | -$847.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$262.30K 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | $585.59K 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $1.23M 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |